FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894066036> ?p ?o ?g. }

• W2894066036 endingPage "1539" @default.
• W2894066036 startingPage "1529" @default.
• W2894066036 abstract "We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6-RET fusion. Although RET fusions have been identified in resistant EGFR-mutant non-small cell lung cancer (NSCLC), their role in acquired resistance to EGFR inhibitors is not well described. To assess the biological implications of RET fusions in an EGFR-mutant cancer, we expressed CCDC6-RET in PC9 (EGFR del19) and MGH134 (EGFR L858R/T790M) cells and found that CCDC6-RET was sufficient to confer resistance to EGFR tyrosine kinase inhibitors (TKI). The selective RET inhibitors BLU-667 and cabozantinib resensitized CCDC6-RET-expressing cells to EGFR inhibition. Finally, we treated 2 patients with EGFR-mutant NSCLC and RET-mediated resistance with osimertinib and BLU-667. The combination was well tolerated and led to rapid radiographic response in both patients. This study provides proof of concept that RET fusions can mediate acquired resistance to EGFR TKIs and that combined EGFR and RET inhibition with osimertinib/BLU-667 may be a well-tolerated and effective treatment strategy for such patients. SIGNIFICANCE: The role of RET fusions in resistant EGFR-mutant cancers is unknown. We report that RET fusions mediate resistance to EGFR inhibitors and demonstrate that this bypass track can be effectively targeted with a selective RET inhibitor (BLU-667) in the clinic.This article is highlighted in the In This Issue feature, p. 1494." @default.
• W2894066036 created "2018-10-05" @default.
• W2894066036 creator A5005314279 @default.
• W2894066036 creator A5006018613 @default.
• W2894066036 creator A5008010635 @default.
• W2894066036 creator A5014411546 @default.
• W2894066036 creator A5028090835 @default.
• W2894066036 creator A5032896791 @default.
• W2894066036 creator A5037376490 @default.
• W2894066036 creator A5044838791 @default.
• W2894066036 creator A5052578824 @default.
• W2894066036 creator A5052791273 @default.
• W2894066036 creator A5056275493 @default.
• W2894066036 creator A5061909254 @default.
• W2894066036 creator A5064382279 @default.
• W2894066036 creator A5065614369 @default.
• W2894066036 creator A5067299042 @default.
• W2894066036 creator A5069070706 @default.
• W2894066036 creator A5072389805 @default.
• W2894066036 creator A5080311196 @default.
• W2894066036 creator A5081227348 @default.
• W2894066036 creator A5084316997 @default.
• W2894066036 creator A5084707465 @default.
• W2894066036 creator A5085217465 @default.
• W2894066036 creator A5085688413 @default.
• W2894066036 creator A5087906702 @default.
• W2894066036 creator A5087923582 @default.
• W2894066036 creator A5087998125 @default.
• W2894066036 creator A5089382639 @default.
• W2894066036 date "2018-12-01" @default.
• W2894066036 modified "2023-10-18" @default.
• W2894066036 title "Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion" @default.
• W2894066036 cites W1546552389 @default.
• W2894066036 cites W1653933658 @default.
• W2894066036 cites W1908940658 @default.
• W2894066036 cites W1969391810 @default.
• W2894066036 cites W1998971866 @default.
• W2894066036 cites W2062291041 @default.
• W2894066036 cites W2088540000 @default.
• W2894066036 cites W2133963438 @default.
• W2894066036 cites W2154149901 @default.
• W2894066036 cites W2160725767 @default.
• W2894066036 cites W2160981405 @default.
• W2894066036 cites W2272802268 @default.
• W2894066036 cites W2285453897 @default.
• W2894066036 cites W2400274474 @default.
• W2894066036 cites W2547345470 @default.
• W2894066036 cites W2560717039 @default.
• W2894066036 cites W2595645511 @default.
• W2894066036 cites W2601368334 @default.
• W2894066036 cites W2619622310 @default.
• W2894066036 cites W2737306670 @default.
• W2894066036 cites W2767615200 @default.
• W2894066036 cites W2770828094 @default.
• W2894066036 cites W2780582854 @default.
• W2894066036 cites W2797098362 @default.
• W2894066036 cites W2805346544 @default.
• W2894066036 cites W2805838497 @default.
• W2894066036 cites W2885289995 @default.
• W2894066036 cites W2890599782 @default.
• W2894066036 cites W2961566889 @default.
• W2894066036 doi "https://doi.org/10.1158/2159-8290.cd-18-1022" @default.
• W2894066036 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6279502" @default.
• W2894066036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30257958" @default.
• W2894066036 hasPublicationYear "2018" @default.
• W2894066036 type Work @default.
• W2894066036 sameAs 2894066036 @default.
• W2894066036 citedByCount "311" @default.
• W2894066036 countsByYear W28940660362018 @default.
• W2894066036 countsByYear W28940660362019 @default.
• W2894066036 countsByYear W28940660362020 @default.
• W2894066036 countsByYear W28940660362021 @default.
• W2894066036 countsByYear W28940660362022 @default.
• W2894066036 countsByYear W28940660362023 @default.
• W2894066036 crossrefType "journal-article" @default.
• W2894066036 hasAuthorship W2894066036A5005314279 @default.
• W2894066036 hasAuthorship W2894066036A5006018613 @default.
• W2894066036 hasAuthorship W2894066036A5008010635 @default.
• W2894066036 hasAuthorship W2894066036A5014411546 @default.
• W2894066036 hasAuthorship W2894066036A5028090835 @default.
• W2894066036 hasAuthorship W2894066036A5032896791 @default.
• W2894066036 hasAuthorship W2894066036A5037376490 @default.
• W2894066036 hasAuthorship W2894066036A5044838791 @default.
• W2894066036 hasAuthorship W2894066036A5052578824 @default.
• W2894066036 hasAuthorship W2894066036A5052791273 @default.
• W2894066036 hasAuthorship W2894066036A5056275493 @default.
• W2894066036 hasAuthorship W2894066036A5061909254 @default.
• W2894066036 hasAuthorship W2894066036A5064382279 @default.
• W2894066036 hasAuthorship W2894066036A5065614369 @default.
• W2894066036 hasAuthorship W2894066036A5067299042 @default.
• W2894066036 hasAuthorship W2894066036A5069070706 @default.
• W2894066036 hasAuthorship W2894066036A5072389805 @default.
• W2894066036 hasAuthorship W2894066036A5080311196 @default.
• W2894066036 hasAuthorship W2894066036A5081227348 @default.
• W2894066036 hasAuthorship W2894066036A5084316997 @default.
• W2894066036 hasAuthorship W2894066036A5084707465 @default.
• W2894066036 hasAuthorship W2894066036A5085217465 @default.
• W2894066036 hasAuthorship W2894066036A5085688413 @default.

• next